Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer

Journal of Clinical Medicine

Marco Mazzotta¹  Federica Tomao²  Eriseld Krasniqi³  Patrizia Vici³  Laura Pizzuti³  Giacomo Barchiesi³  Maddalena Barba³ 

[1] Department of Clinical and Molecular Medicine, “Sapienza” University of Rome, Azienda Ospedaliera Sant’Andrea, 00189 Rome, Italy;Department of Gynecology-Obstetrics and Urology, “Sapienza” University of Rome, 00161 Rome, Italy;Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy;

关键词: HER2 positive breast cancer;    trastuzumab;    long-term safety;    efficacy;    real-world settings;   

DOI  :  10.3390/jcm8020254

来源: DOAJ

【 摘 要 】

Trastuzumab is a milestone in the treatment of human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC), in both the early and metastatic settings. Over the last two decades, clinical trials have established the good safety profile of trastuzumab. Cardiotoxicity remains the most frequent adverse event, more commonly exemplified by an asymptomatic decline in the left ventricular ejection fraction rather than congestive heart failure. Results from several long-term (>5 years) safety analyses have been recently published, with the inherent evidence substantially confirming the findings from previous trials. The clinical experience gained over the years in the use of trastuzumab has also fueled a number of observational studies focused on the effectiveness of this drug in the real-world settings. We herein reviewed the evidence available from tree major databases, namely, PubMed, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL), to explore and critically discuss key issues related to the long-term safety and effectiveness of trastuzumab in clinical practice.

【 授权许可】

Unknown